FDA Clearance Tracker · P970004-S210
MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL
Last checked: Nov 20, 2026Latest source record: Apr 21, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Apr 21, 2016
Approved
Time to decision
73 days
Received Feb 8, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P970004-S210
- Device name
- MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL
- Applicant
- Medtronic Neuromodulation
- Applicant location
- Minneapolis, MN
- Received
- Feb 8, 2016
- Decided
- Apr 21, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P970004
Device type
- Device class
- Class III
- Regulation
- 21 CFR 876.5270
FDA's approval statement
As written in FDA's record.
Approval for changes made to the Model 8840 N'Vision® Clinician Programmer including replacement of PCBA components, liquid crystal display assembly changes, compact flash card housing and programmer housing design changes, infrared data association transceiver changes, static random access memory changes, electromagnetic interference shield changes, telemetry module platform software updates, clinical programmer base module platform software updates, Physician Manual labeling changes, EMC Declaration changes, device labeling changes and packaging labeling changes.
Source documents
Other decisions for Medtronic Neuromodulation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240011 · Decided Sep 18, 2025 · 532 days after receipt
Device type: Stimulator, tibial, electrical, implantable, for urinary incontinence (QPT) · GI, Urology & Nephrology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.